Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04656041 · ClinicalTrials.gov registry record · Phase 2
Folfox+Irinotecan+Chemort In Esophageal Cancer
A Phase 2 study of Gastroesophageal Junction Adenocarcinoma and Esophagogastric Cancer, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT04656041 is a Phase 2 study of Gastroesophageal Junction Adenocarcinoma and Esophagogastric Cancer that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 40 participants, below the 403-participant average among 40 other Gastroesophageal Junction Adenocarcinoma trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT04656041, a Phase 2 study of Gastroesophageal Junction Adenocarcinoma and Esophagogastric Cancer, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
In this research study, is studying how Liposomal Irinotecan in combination with the standard of care interventions FOLFOX, carboplatin paclitaxel, and radiation therapy affect gastroesophageal junction or esophagogastric cancer This research study involves the following study intervention: \- Liposomal irinotecan
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG FOLFOX/ nal-IRI
- RADIATION Proton Radiation Therapy
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth-Israel Deaconess Medical Center - Boston
- Massachusetts General Hospital at Newton Wellesley Hospital - Newton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-06-29 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04656041
The ClinicalTrials.gov registry entry for NCT04656041 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 403-participant average among 40 other Gastroesophageal Junction Adenocarcinoma trials with a reported enrollment target (90% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gastroesophageal Junction Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT04656041 reports 3 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04656041 about?
NCT04656041 is a clinical study titled "Folfox+Irinotecan+Chemort In Esophageal Cancer". In this research study, is studying how Liposomal Irinotecan in combination with the standard of care interventions FOLFOX, carboplatin paclitaxel, and radiation therapy affect gastroesophageal junction or esophagogastric cancer This research study involves the following study intervention: \- Lip...
What is the current status of trial NCT04656041?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2021-06-29. Estimated completion is 2027-12.
What conditions does trial NCT04656041 study?
This clinical trial studies the following conditions: Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer.
What interventions are being tested in trial NCT04656041?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), FOLFOX/ nal-IRI (DRUG), Proton Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT04656041?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04656041 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Junction Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RECRUITING · Phase 2
-
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
RECRUITING · Phase 2
-
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Gastroesophageal Junction Adenocarcinoma
All registered trials for this condition
Esophagogastric Cancer
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.